ArticleCell2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Erratum issued 3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 903 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
903citing papers in PubMed, 1 pooled it
68.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
An Open-label, Single-arm Exploratory Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer
NCT06685354 phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation
Sequential Targeted and Immunotherapy With Recombined Human Type 5 Adenovirus Via Hepatic Arterial Infusion for BCLC Stage C Hepatocellular Carcinoma: A Prospective Single-Center Single-Arm Pilot Study
Who cites it
903 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,452 citations in OpenAlex.
- Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.Journal of virology · 2025Pooled it
- Trial
- Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).Nature communications · 2026Trial
- Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.Journal for immunotherapy of cancer · 2025Trial
- Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.Journal for immunotherapy of cancer · 2025Trial
- Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).Nature cancer · 2025Trial
- Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.Nature medicine · 2025Trial
- A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Trial
- Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.Nature medicine · 2024Trial
- Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Trial
- Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot.Human vaccines & immunotherapeutics · 2026Review
- Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review).Oncology reports · 2026Review
- Resistance to PD-1/PD-L1 blockade: Mechanism and pharmacological strategies.Pharmacological research · 2026Review
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.Science advances · 2026Article
- Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner.Molecular therapy. Oncology · 2026Article
- Oncolytic virus-mediated remodeling of tumor microenvironment enhances efficacy of an HPV16 E6/E7 mRNA vaccine in an HPV-positive tumor.Molecular therapy. Oncology · 2026Article
- Comprehensive preclinical evaluation of second-generation miRNA-regulated Coxsackievirus B3-BHP: Potent antitumor efficacy and safety.Molecular therapy. Oncology · 2026Article
- Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.Nature reviews. Clinical oncology · 2026Review
- Tuning epigenetics to enhance cancer virotherapy.Acta pharmaceutica Sinica. B · 2026Review
843 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
20 authors at 16 institutions in 4 countries.
Antoni RibasUniversity of California at Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address: aribas@mednet.ucla.edu.
Reinhard DummerUniversity Hospital of Zurich, Zurich, Switzerland.
Igor PuzanovRoswell Park Cancer Institute, Buffalo, NY, USA.
Ari VanderWaldeThe West Clinic, Memphis, TN, USA.
Robert H I AndtbackaUniversity of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Olivier MichielinCentre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Anthony J OlszanskiFox Chase Cancer Center, Philadelphia, PA, USA.
Josep MalvehyHospital Clinic i Provincial de Barcelona, Barcelona, Spain.
Jonathan CebonOlivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, LaTrobe University, Heidelberg, VIC, Australia.
Eugenio FernandezHopitaux Universitaires de Genève, Geneva, Switzerland.
John M KirkwoodUniversity of Pittsburgh Cancer Institute and Hillman UPMC Cancer Center, Pittsburgh, PA, USA.
Thomas F GajewskiThe University of Chicago School of Medicine, Chicago, IL, USA.
Lisa ChenAmgen Inc., Thousand Oaks, CA, USA.
Kevin S GorskiAmgen Inc., South San Francisco, CA, USA.
Abraham A AndersonAmgen Inc., Thousand Oaks, CA, USA.
Scott J DiedeMerck & Co., Inc., Kenilworth, NJ, USA.
Michael E LassmanMerck & Co., Inc., Kenilworth, NJ, USA.
Jennifer GansertAmgen Inc., Thousand Oaks, CA, USA.
F Stephen HodiDana-Farber Cancer Institute, Boston, MA, USA.
Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
Amgen (United States) · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USCampbell Clinic · USDana-Farber Cancer Institute · USFox Chase Cancer Center · USHôpital Beau-Séjour · CHHospital Clínic de Barcelona · ESLa Trobe University · AUMelanoma Institute Australia · AURoswell Park Comprehensive Cancer Center · USUniversity Hospital of Lausanne · CHUniversity Hospital of Zurich · CHUniversity of California, Los Angeles · USUniversity of Chicago · USUniversity of Utah · USUPMC Hillman Cancer Center · US
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8MWomen's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6MTransductionally Redirected /Transcriptionally RestricteP50CA086306 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HERSCHMAN, HARVEY R. · 2000 to 2014
$29.0MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4MStrategies for Distinguishing Success in Immunotherapy Treatments (PQ20)R01CA170689 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HEATH, JAMES R., RIBAS, ANTONI · 2012 to 2015
$2.5MNCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA016042NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA086306NCI NIH HHS R01 CA170689NCI NIH HHS R35 CA197633
Abstract
Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurred. Confirmed objective response rate was 62%, with a complete response rate of 33% per immune-related response criteria. Patients who responded to combination therapy had increased CD8
Indexed as
Antibodies, Monoclonal, HumanizedCombined Modality TherapyHerpesviridaeHumansImmunotherapyMelanomaOncolytic VirotherapyProgrammed Cell Death 1 ReceptorTumor MicroenvironmentAntibodies, Monoclonal, HumanizedPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptoranti-PD-1biomarkerscytotixicinterferon gammamelanomaoncolytic immunotherapyoncolytic virusespembrolizumabtalimogene laherparepvecT lymphocytestumortumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.